London – October 01, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.
TGA Grants Class IIb Status to QMID on September 15, 2026
The device, developed with Jupiter Research LLC, was listed in the Australian Register of Therapeutic Goods as a Class IIb Medical Device, marking the first regulatory approval in Australia for a device delivering Cannabis Sativa L. extracts via patient inhalation. The approval follows a multi-year regulatory process and arrives one year after QMID received EU Medical Device Registration.
New Zealand Listing Follows Two Days Later Through Medsafe
QMID was added to Medsafe's Web Assisted Notification of Devices database on September 17, 2026, making it available to New Zealand prescribers. Vicki Partridge Pty Ltd is acting as sponsor for both the Australian and New Zealand markets.
Approval Closes a Device Gap That Left Prescribed Medicines Unusable
While cannabis medicines themselves move through TGA-approved prescribing pathways, the inhalation devices used to administer them have largely sat outside the ARTG. Prescribers and pharmacists have struggled to secure approvals for unregistered batteries, at times leaving patients holding a valid prescription with no compliant device to use it. The regulator has repeatedly demanded clinical justification for unapproved devices in such cases; QMID now offers a formally assessed alternative.
Device Now Operates in Seven Countries After May 2025 EU Certification
QMID first achieved Class IIa certification under EU Medical Device Regulation (EU) 2017/745 in May 2025, becoming the first handheld liquid inhalation device for consistent medical cannabis administration to clear that framework. The Australian and New Zealand listings extend its international rollout to seven countries. The hardware is reusable but compatible only with approved cartridges, and is engineered to deliver controlled aerosolization for comparable clinical dosing data.
Executives Frame Dual EU-Australia Clearance as a Market Differentiator
Curaleaf International CEO Juan Martinez said QMID is the first liquid cannabis inhalation device approved under both EU and Australian medical device frameworks, crediting the TGA's insistence that delivery devices meet the same standards as the medicines they dispense. Chief Medical Officer Dr Mikael Sodergren said the registration allows clinicians in Australia and New Zealand to prescribe a formally approved device with standardized dosing for the first time, comparable to other regulated medicines.